-+ 0.00%
-+ 0.00%
-+ 0.00%

Freedom Capital Markets Upgrades Alnylam Pharmaceuticals to Buy, Lowers Price Target to $410

Benzinga·02/17/2026 14:46:14
Listen to the news
Freedom Capital Markets analyst Ilya Zubkov upgrades Alnylam Pharmaceuticals (NASDAQ:ALNY) from Hold to Buy and lowers the price target from $470 to $410.